Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stoke Therapeutics, Inc. (Nasdaq: STOK) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures. As a Nasdaq Global Select Market issuer, Stoke files current reports, annual reports, and other documents that describe its financial condition, governance, and progress in developing RNA-based medicines such as zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Current reports on Form 8-K document material events, including quarterly financial results, clinical and collaboration milestones, and changes in executive leadership. For example, Stoke has used Form 8-K to announce results of operations, disclose the appointment of its Chief Executive Officer and related employment and severance agreements, and furnish press releases about the initiation and progress of the global Phase 3 EMPEROR study of zorevunersen and the Phase 1 OSPREY study of STK-002.
Amended current reports on Form 8-K/A provide additional detail or updates on previously reported items, such as the company’s decisions regarding the frequency of advisory shareholder votes on executive compensation. These filings offer insight into Stoke’s corporate governance practices and board decisions.
Through Stock Titan, investors can also track periodic filings such as Forms 10-K and 10-Q when available, which typically include detailed discussions of Stoke’s TANGO antisense platform, its rare disease pipeline, collaboration agreements, and risk factors. Form 4 and related insider transaction filings, when present, can help users monitor equity awards and share transactions by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand the significance of items such as clinical trial disclosures, collaboration terms, compensation arrangements, and shareholder voting outcomes. Real-time updates from the SEC’s EDGAR system ensure that new STOK filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are surfaced promptly for further review and analysis.
Amendment No. 5 to Schedule 13D updates the ownership position of the reporting group — Skorpios Trust, Montrago Trustees Ltd., Blue Horizon Enterprise Ltd. and Ezbon International Ltd. — in Stoke Therapeutics (STOK).
The group now reports beneficial ownership of roughly 6.23 million shares, or 11.4 % of the 54.6 million shares outstanding as disclosed in STOK’s 30 April 2025 10-Q. Current individual blocks are:
- Blue Horizon: 2,967,621 shares (5.4 %) with shared voting/dispositive power
- Montrago Trustees & Skorpios Trust: 3,256,181 shares each, reflecting the same 6 % stake held jointly
- Ezbon International: 288,560 shares (0.5 %)
Key event: On 18 June 2025 Ezbon sold 650,000 shares at $11.00 in an open-market trade, cutting its holdings by ~69 % and raising about $7.2 million. No other trades were reported within the past 60 days.
A new Joint Filing Agreement dated 23 June 2025 is filed as Exhibit 1. Aside from Ezbon’s sale, prior disclosures remain unchanged.
While the group continues to exceed the 10 % threshold, Ezbon’s sizable disposal may signal reduced conviction or liquidity needs, and could introduce incremental supply pressure if additional sales follow. Investors should monitor forthcoming filings for further changes to this concentrated insider position.
Stoke Therapeutics (STOK) – Form 3 initial beneficial ownership disclosure
Chief Patient Officer Jason Hoitt has filed his first Section 16 statement. He directly owns 1,802 common shares of Stoke Therapeutics. In addition, he holds 480,000 employee stock options across four grants: 265,000 options at $12.21 expiring 04/14/2034; 65,000 at $14.25 expiring 08/14/2034; 60,000 at $8.33 expiring 03/19/2035; and 90,000 at $11.70 expiring 06/15/2035. Vesting schedules follow the standard 25% cliff after one year, with the remainder vesting monthly, subject to continued employment. Hoitt was also granted 40,000 restricted stock units (RSUs) that vest 25% annually starting 03/15/2026.
The filing is informational only—no shares were bought or sold. While the equity package is meaningful for the executive, it represents a small fraction of the company’s total shares outstanding and is unlikely to move the market. Nonetheless, the disclosure demonstrates alignment of management incentives with shareholder interests.